Hero Image

Emgality can help give you more migraine-free days

Emgality reduced the average number of migraine days each month in adults

Select Important Safety Information
Do not use Emgality if you are allergic to galcanezumab-gnlm or any of the ingredients in Emgality.


Experience Emgality for free for up to 12 months if you're eligible and commercially insured*

To do this, we will need your HIPAA authorization to work on your behalf to help you pay as little as possible. Requesting an Emgality savings card shouldn’t take more than a few minutes.

As a reminder, HIPAA is the Health Insurance Portability and Accountability Act that provides data privacy and security to protect your medical information.

*Terms and Conditions:
Offer good for up to 12 months until 12/31/2020 if healthcare provider submits a prior authorization form or coverage exception request, when required, to the patient’s insurance provider. $0 monthly offer for commercially insured with insurance provider coverage, subject to wholesale acquisition cost plus usual and customary pharmacy charges and a separate $4900 maximum annual cap. $0 monthly offer for commercially insured without insurance provider coverage, subject to separate monthly and annual cap of wholesale acquisition cost plus usual and customary pharmacy charges. This offer is not available for patients without commercial insurance coverage or those whose prescription claims are eligible to be reimbursed, in whole or in part, by Medicare Part D, Medicaid, TRICARE, or any other state or federal program. Offer void where prohibited by law and subject to change or discontinue without notice. Card activation is required. Subject to additional terms and conditions, which can be found here.

Experience once-monthly dosing with Emgality

Following an initial loading dose of 240 mg (two injections of 120 mg each)

Experience Once-Monthly Dosing Image

Help prevent migraine days before they start


For those who had 4-14 migraine days per month,
Emgality cut the number of monthly migraine days by:

75% or more for some patients

In a study, the number of people with ≥15 headache days per month who achieved 75% reduction in monthly migraine days did not differ from people taking placebo.


For those who had 15 or more headache days per month,
Emgality cut the number of monthly migraine days by:

50% or more for some patients
Indications and Important Safety Information
Indication

Emgality is indicated for the preventive treatment of migraine in adults.

Important Safety Information about Emgality (galcanezumab-gnlm)

Do not use Emgality if you are allergic to galcanezumab-gnlm or any of the ingredients in Emgality.


Emgality may cause serious side effects, including: allergic reactions, such as itching, rash, hives, and trouble breathing. Allergic reactions can happen days after using Emgality. Call your healthcare provider or get emergency medical help right away if you have any of the following symptoms, which may be part of an allergic reaction:

  • swelling of your face, mouth, tongue, or throat
  • trouble breathing

Before you use Emgality, tell your healthcare provider if you are:

  • pregnant or plan to become pregnant. It is not known if Emgality will harm your unborn baby
  • breastfeeding or plan to breastfeed. It is not known if Emgality passes into breast milk
  • taking any prescription or over-the-counter medicines, vitamins, or herbal supplements

The most common side effects of Emgality include: Injection site reactions


Tell your healthcare provider if you have any side effect that bothers you or does not go away. These are not all the possible side effects of Emgality. For more information, ask your healthcare provider or pharmacist.


You can report side effects to the Food and Drug Administration (FDA) at www.fda.gov/medwatch or by calling 1-800-FDA-1088.


Emgality is available by prescription only.


Please see Prescribing Information, including Patient Information, for Emgality. See Instructions for Use included with the pen and prefilled syringe.


GZ CON ISI 27SEP2018